GlassScriptPhysician profile
Charya Goldsmith
NPI 1164742425
$9,163.43
in general payments reported to CMS, 2019-2025
34 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $598 · 2021: $1,132 · 2022: $860 · 2023: $1,267 · 2024: $2,031 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,569 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,568.55 |
| Education | $122.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,965.87 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Janssen Biotech, INC. | $729.57 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $704.42 | 2019-2025 | |
| Genzyme Corporation | $649.25 | 2019-2025 | |
| Ucb, INC. | $633.69 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $622.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $584.79 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $493.01 | 2019-2025 | Adbry, Spevigo |
| Lilly USA, LLC | $396.24 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $331.88 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Arcutis Biotherapeutics, INC. | $244.07 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $213.49 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $209.43 | 2023-2025 | Opzelura |
| Genentech USA, INC. | $164.14 | 2019-2021 | |
| Organogenesis INC. | $143.17 | 2021-2023 | Puraply |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.26 | 2019-2024 | Otezla |
| Mayne Pharma Commercial LLC | $119.59 | 2019-2025 | |
| Organon LLC | $115.10 | 2025 | Hadlima, Vtama |
| Almirall LLC | $112.42 | 2021-2024 | Klisyri, Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.79 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.64 | 2019-2025 | Jublia |
| Dermavant Sciences, INC. | $62.20 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $60.13 | 2024 | Ycanth |
| Botanix Sb INC | $47.36 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $45.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.74 | 2023-2024 | Sotyktu |
| Merck Sharp & Dohme LLC | $27.58 | 2019 | |
| Encore Dermatology INC. | $23.61 | 2020 | |
| Journey Medical Corporation | $22.09 | 2022 | |
| Aclaris Therapeutics, INC. | $20.97 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.69 | 2019 | |
| Dermira, INC. | $15.38 | 2021 | |
| Polynovo North America LLC | $14.84 | 2025 | Novosorb Btm |
| Fidia Pharma USA INC. | $13.79 | 2025 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charya Goldsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.